Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

The Scottish Inflammatory Prognostic Score (SIPS), derived from serum albumin and neutrophil count integrates inflammatory and nutritional status. However, its prognostic role in advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors remains unclear. This multicenter, retrospective study included 816 patients with advanced or metastatic NSCLC who received nivolumab following platinum-based chemotherapy between January 2015 and January 2025 at 19 oncology centers in Turkey. The SIPS was calculated at baseline by assigning one point each for albumin < 35 g/L and neutrophil count > 7.5 × 10⁹/L, classifying patients as favorable (0), intermediate (1), or poor (2). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis and compared using the log-rank test. Cox regression models were used to identify independent prognostic factors. The median OS decreased across the SIPS groups: 15.0 months (95% CI 12.9–17.1), 8.0 months (95% CI 5.3–10.7), and 5.0 months (95% CI 3.5–6.5) for the favorable, intermediate, and poor groups, respectively (p < 0.001). The median PFS was 7.0, 4.0, and 2.0 months (p < 0.001). In the multivariate analysis, SIPS remained independently associated with both OS (HR = 3.19, 95% CI 1.90–5.35, p < 0.001) and PFS (HR = 3.02, 95% CI 1.89–4.84, p < 0.001). Baseline SIPS is a simple, cost-effective, and independent prognostic biomarker in nivolumab-treated NSCLC. Prospective studies are needed to validate these findings and evaluate its integration with other markers to improve clinical risk stratification and may be useful for prognostic assessment.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-04-21
DOI
https://doi.org/10.1007/s12672-026-04859-8
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

Umut Kefeli, Teoman Şakalar, Latif Karahan, Berrak Mermit Erçek et al.
Discover Oncology
Inflammatory Biomarkers in Disease Prognosis
article

Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

Umut Kefeli, Teoman Şakalar, Latif Karahan, Berrak Mermit Erçek, Oktay Bozkurt, Cengiz Akosman, Hayati Arvas, Gözde Ağdaş, Sedat Biter, Erkam Kocaaslan, Sedat Yıldız, Erdem Kolemen, Emel Mutlu Ozkan, Ayse Nuransoy Cengiz, Mehmet Mutlu Kidi, Kazim Uygun, Aslihan Ezgi Apaydin Rollas, Pervin Can Sanci, Hacer Demir, Deniz Can Güven, Mustafa Ersoy, Havva Yeşil Cinkir, Anıl Karakayalı, Ezgi Türkoğlu, Sedat Yıldırım, Muslih Urun, Nargiz Majidova, Muhammet Cengiz, Duygu Bayır, Devrim Çabuk, Tolga Köseci, Mustafa Erman, Elif Şahin, Saadettin Kılıçkap
article en

Abstract

The Scottish Inflammatory Prognostic Score (SIPS), derived from serum albumin and neutrophil count integrates inflammatory and nutritional status. However, its prognostic role in advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors remains unclear. This multicenter, retrospective study included 816 patients with advanced or metastatic NSCLC who received nivolumab following platinum-based chemotherapy between January 2015 and January 2025 at 19 oncology centers in Turkey. The SIPS was calculated at baseline by assigning one point each for albumin < 35 g/L and neutrophil count > 7.5 × 10⁹/L, classifying patients as favorable (0), intermediate (1), or poor (2). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis and compared using the log-rank test. Cox regression models were used to identify independent prognostic factors. The median OS decreased across the SIPS groups: 15.0 months (95% CI 12.9–17.1), 8.0 months (95% CI 5.3–10.7), and 5.0 months (95% CI 3.5–6.5) for the favorable, intermediate, and poor groups, respectively (p < 0.001). The median PFS was 7.0, 4.0, and 2.0 months (p < 0.001). In the multivariate analysis, SIPS remained independently associated with both OS (HR = 3.19, 95% CI 1.90–5.35, p < 0.001) and PFS (HR = 3.02, 95% CI 1.89–4.84, p < 0.001). Baseline SIPS is a simple, cost-effective, and independent prognostic biomarker in nivolumab-treated NSCLC. Prospective studies are needed to validate these findings and evaluate its integration with other markers to improve clinical risk stratification and may be useful for prognostic assessment.

Discover Oncology
Van Yüzüncü Yıl Üniversitesi (TR), Dicle University (TR), Ministry of Health (TR), Heidelberg University (DE), Hitit Üniversitesi (TR), University Hospital Heidelberg (DE), Kütahya Dumlupınar Üniversitesi (TR), Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR), Medical Park Gaziantep Hospital (TR), Istinye University (TR), Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi (TR), Afyonkarahisar Sağlık Bilimleri Üniversitesi, Maltepe University (TR), Eskişehir Osmangazi University (TR), Kocaeli Üniversitesi (TR), Afyon Kocatepe University (TR), Cukurova University (TR), Gaziantep University (TR), Hacettepe University (TR), Marmara University (TR), Erciyes University (TR)
Zero hunger
Openalex Percentile: Top 17%
Inflammatory Biomarkers in Disease Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.